Abstract
Purpose/Objective: In most multimodality treatment approaches of NSCLC as well as in boost therapy of definitive radiation therapy, the irradiated volume is restricted to the primary tumor and known nodal involvement with a 1-2 cm margin. Hence, an exact localization of nodal involvement and of the primary tumor extent is crucial for success and related toxicity of radiation therapy. To determine the role of 2-[(18)F] fluoro-2- deoxy-D-glucose (FDG) positron emission tomography (PET) in therapeutic management and 3D-radiation therapy planning, findings in 36 patients were analyzed prospectively in an ongoing multicenter trial (LUCAS-MD).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Radiation Oncology*Biology*Physics
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
